EC
CYTK icon

Elequin Capital’s Cytokinetics CYTK Stock Holding History

Elequin Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-75
Closed -$4.94K – 755
2026
Q1 		$4.94K Sell
75
-131
-64% -$8.33K ﹤0.01% 385
2025
Q4 		$13.1K Buy
+206
New +$12.8K ﹤0.01% 215
2025
Q1 		– Sell
-207
Closed -$9.74K – 396
2024
Q4 		$9.74K Buy
207
+57
+38% +$2.96K ﹤0.01% 348
2024
Q3 		$7.92K Buy
+150
New +$8.36K ﹤0.01% 257
2023
Q3 		– Sell
-258
Closed -$8.42K – 448
2023
Q2 		$8.42K Buy
+258
New +$9.55K ﹤0.01% 320
2022
Q4 		– Sell
-265
Closed -$13K – 646
2022
Q3 		$13K Buy
+265
New +$12.8K ﹤0.01% 221

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Elequin Capital's CYTK Position: Q2 2026 in Review

Elequin Capital sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 75 shares — an estimated $4.94K sold.

Elequin Capital first reported a position in CYTK in Q3 2022 and held it in 6 quarters. The position peaked at $13.1K in Q4 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Elequin Capital reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Elequin Capital sold 75 Cytokinetics shares in Q2 2026, an estimated $4.94K.
  • Elequin Capital first reported a position in Cytokinetics in Q3 2022 and held it in 6 quarters.
  • Elequin Capital's Cytokinetics position peaked at $13.1K in Q4 2025.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Elequin Capital's 13F filing for Q2 2026, filed 13 Aug 2026.